Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 264Carcinoma, Renal Cell 93Urinary Bladder Neoplasms 72Breast Neoplasms 42Carcinoma, Transitional Cell 39Colorectal Neoplasms 34Ovarian Neoplasms 33Kidney Neoplasms 32Carcinoma, Non-Small-Cell Lung 32Melanoma 31Neoplasms 28Neoplasm Metastasis 28Sarcoma 25Uterine Cervical Neoplasms 21Lung Neoplasms 21Endometrial Neoplasms 21Non-Muscle Invasive Bladder Neoplasms 20Wilms Tumor 18Pancreatic Neoplasms 18Carcinoma, Hepatocellular 17Adenocarcinoma 17Stomach Neoplasms 16Triple Negative Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Metastatic Castration-resistant Prostate Cancer 13Head and Neck Neoplasms 13Esophageal Neoplasms 13Rhabdomyosarcoma 12Osteosarcoma 12Neuroblastoma 12

Interventions

enzalutamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Prostate Cancer × Genitourinary × 30 days × Clear all
NCT07198633 2026-06-02

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Recruiting
212 enrolled
Genitourinary

Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡